新诺威(300765) - 2023 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2023 reached ¥684,020,305, representing a 26.43% increase compared to ¥541,028,381 in the same period last year[5] - Net profit attributable to shareholders was ¥181,976,426, a 47.33% increase from ¥123,520,129 in Q1 2022[5] - The net profit after deducting non-recurring gains and losses was ¥179,439,429, reflecting a 60.88% increase from ¥111,537,005 in the previous year[5] - Total operating revenue for Q1 2023 was CNY 684,020,305, representing an increase of 26.4% compared to CNY 541,028,381.87 in the same period last year[23] - Net profit for Q1 2023 reached CNY 181,929,887.41, representing a 47.2% increase from CNY 123,502,450.15 in Q1 2022[24] - The company reported a total comprehensive income of CNY 181,810,781.12 for Q1 2023, up from CNY 123,843,650.92 in the same period last year[25] - Basic and diluted earnings per share for Q1 2023 were CNY 0.2939, compared to CNY 0.1995 in Q1 2022, marking a 47.3% increase[25] Cash Flow and Liquidity - Operating cash flow net amount was ¥156,910,520, up 47.53% from ¥106,355,966 in Q1 2022[12] - Cash and cash equivalents at the end of Q1 2023 were ¥2,799,277,798, a 63.81% increase from ¥1,708,827,432 at the end of the previous year[12] - The company's cash and cash equivalents at the end of Q1 2023 amounted to CNY 2,802,092,881.57, up from CNY 2,195,684,427.95 at the beginning of the year, reflecting a growth of 27.6%[20] - The company raised CNY 488,799,998.48 through financing activities in Q1 2023, compared to a cash outflow of CNY 736,892.33 in the same period last year[28] Assets and Liabilities - Total assets at the end of Q1 2023 were ¥5,180,768,085, a 13.02% increase from ¥4,584,035,512 at the end of the previous year[5] - The total assets as of March 31, 2023, were CNY 5,180,768,084.66, compared to CNY 4,584,035,512.38 at the beginning of the year, indicating an increase of 13.0%[21] - The total liabilities decreased from CNY 639,841,376.25 at the beginning of the year to CNY 566,567,751.88, a reduction of 11.4%[21] - The equity attributable to shareholders of the parent company increased to CNY 4,605,653,369.51 from CNY 3,935,600,634.14, marking a growth of 17.0%[21] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 17,983, with the top 10 shareholders holding 73.35% of the shares[13] - The total number of unrestricted shares held by the top 10 shareholders includes 404,135,550 shares held by Shiyao Group Enbipu Pharmaceutical Co., Ltd.[14] - UBS AG holds 3,211,586 shares, representing 0.51% of the total shares[14] - The total number of shares held by the top shareholder, Shiyao Group Enbipu Pharmaceutical Co., Ltd., is 404,135,550 shares, all of which are ordinary shares[14] - The total number of shares held by Hong Kong Central Clearing Limited is 6,052,856, representing 0.93% of the total shares[14] Research and Development - The company's R&D expenses increased by 79.97% to ¥13,545,879 from ¥7,526,576 in the same period last year, indicating a focus on innovation[11] - Research and development expenses increased to CNY 13,545,879.02, up 80.5% from CNY 7,526,575.82 in the previous year[24] Operational Highlights - The company completed the election of a new board of directors and supervisory board on April 7, 2023, along with the appointment of new senior management[18] - The company plans to continue expanding its market presence and investing in new product development to drive future growth[18] - Total operating costs for Q1 2023 were CNY 472,576,687.19, an increase of 22.4% compared to CNY 386,256,108.97 in Q1 2022[24] - The company experienced a foreign exchange loss of CNY 4,787,109.33 during Q1 2023, compared to a gain of CNY 81,750.42 in Q1 2022[28]